Seferović, P. M., Fragasso, G., Petrie, M., Mullens, W., Ferrari, R., Thum, T., Bauersachs, J., Anker, S. D., Ray, R., Çavuşoğlu, Y., Polovina, M., Metra, M., Ambrosio, G., Prasad, K., Seferović, J., Jhund, P. S., Dattilo, G., Čelutkiene, J., Piepoli, M., Moura, B., Chioncel, O., Ben Gal, T., Heymans, S., de Boer, R. A., Jaarsma, T., Hill, L., Lopatin, Y., Lyon, A. R., Ponikowski, P., Lainščak, M., Jankowska, E., Mueller, C., Cosentino, F., Lund, L., Filippatos, G. S., Ruschitzka, F., Coats, A. J., & Rosano, G. M. (2020). sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. European journal of heart failure, 22, 1495–1503. http://access.bl.uk/ark:/81055/vdc_100113735688.0x00002e